Close Menu

NEW YORK (GenomeWeb) – Danaher today reported that total sales for the second quarter rose 10 percent year over year and beat the consensus Wall Street estimate. 

For the three months ending June 29, the Washington, DC-based conglomerate posted $4.98 billion in sales, up from $4.51 billion in Q2 2017. Analysts' average sales estimate was $4.92 billion. 

Organically, sales were up 6 percent year over year. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.

There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.

The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.

In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.